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Abstract The extracellular signal-regulated kinase 1/2
(ERK1/2) mitogen-activated protein kinase (MAPK) sig-
nalling pathway regulates many cellular functions,
including proliferation, differentiation, and transformation.
To reliably convert external stimuli into specific cellular
responses and to adapt to environmental circumstances, the
pathway must be integrated into the overall signalling
activity of the cell. Multiple mechanisms have evolved to
perform this role. In this review, we will focus on negative
feedback mechanisms and examine how they shape ERK1/
2 MAPK signalling. We will first discuss the extensive
number of negative feedback loops targeting the different
components of the ERK1/2 MAPK cascade, specifically
the direct posttranslational modification of pathway com-
ponents by downstream protein kinases and the induction
of de novo gene synthesis of specific pathway inhibitors.
We will then evaluate how negative feedback modulates
the spatiotemporal signalling dynamics of the ERK1/2
pathway regarding signalling amplitude and duration as
well as subcellular localisation. Aberrant ERK1/2 activa-
tion results in deregulated proliferation and malignant
transformation in model systems and is commonly
observed in human tumours. Inhibition of the ERK1/2
pathway thus represents an attractive target for the treat-
ment of malignant tumours with increased ERK1/2
activity. We will, therefore, discuss the effect of ERK1/2
MAPK feedback regulation on cancer treatment and how it
contributes to reduced clinical efficacy of therapeutic
agents and the development of drug resistance.
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Introduction
The ERK1/2 MAPK pathway
Eukaryotic cells respond to changes in their environment
through complex and interconnected signal transduction
networks that convert external stimuli into a range of cel-
lular responses. A common motif by which extracellular
modulation of cell-surface receptor activity is transduced
into a specific cellular response is the three-tiered mitogen-
activated protein kinase (MAPK) cascade, with the extra-
cellular signal-regulated kinase 1/2 (ERK1/2) pathway
being the most extensively investigated. The principal
mechanisms involved in the activation of the ERK1/2
pathway have been well characterised [1]. In brief, sig-
nalling is initiated when an extracellular ligand binds to a
specific receptor tyrosine kinase (RTK) at the plasma
membrane. This promotes receptor dimerisation and
autophosphorylation on intracellular tyrosine residues that
then act as recognition sites for proteins containing Src
homology 2 (SH2) or phosphotyrosine binding (PTB)
domains, including the adaptor proteins Shc and Grb2. Son
of sevenless (SOS) is then recruited from the cytosol to the
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plasma membrane through Shc and Grb2 and acts as the
major guanine nucleotide exchange factor (GEF) that
catalyses the conversion of inactive Ras-GDP to active
Ras-GTP [2]. Activated Ras-GTP then recruits Raf to the
plasma membrane, where it is activated in a complex
fashion (for review, see [3, 4]). Once activated, all Raf
family members (A-Raf, B-Raf, and c-Raf (Raf-1) [5]) are
capable of activating MEK1/2, which in turn activates
ERK1/2. This is achieved by phosphorylation in the acti-
vation segment of their respective kinase domains. The
ultimate outcome is the phosphorylation of a large variety
of critical targets by ERK1/2. Over 150 ERK1/2 substrates,
including many nuclear transcription factors, have been
identified [6]. The specific set of targets that are phos-
phorylated under particular extra- and intracellular
conditions determines the appropriate response of the cell.
Regulation of the ERK1/2 signalling pathway
To adapt to particular environmental circumstances, the
ERK1/2 MAPK pathway must be integrated into the
overall signalling activity of the cell. Importantly, the
magnitude, duration, and location of MAPK signalling
must be strictly controlled to produce the correct biological
response. Multiple mechanisms have evolved to perform
this role, including positive and negative feedback loops as
well as extensive cross talk between parallel pathways. In
this review, we will focus on negative feedback and the
mechanisms by which it shapes ERK1/2 MAPK signalling.
Negative feedback loops targeting the ERK1/2 MAPK
cascade fall into two main categories: direct posttransla-
tional modification of pathway components and the
induction of de novo gene synthesis of specific pathway
inhibitors. The principal difference between these two
mechanisms is the time required to take effect. While direct
posttranslational modification is nearly instantaneous, de
novo gene expression and protein synthesis is somewhat
delayed following the initial pathway activation. In this
review, we will discuss in detail how negative feedback
determines ERK1/2 spatiotemporal signalling dynamics
and the role of negative feedback regulation in the devel-
opment and treatment of cancer.
Inhibitory feedback phosphorylation
by downstream kinases
Nearly all components of the ERK1/2 MAPK cascade are
regulated through negative feedback phosphorylation by
downstream kinases. The negative feedback phosphoryla-
tion events that have been studied in reasonable detail are
summarised in Table 1 and Fig. 1 and will be further dis-
cussed in this article.
Growth factor receptors
ERK1/2 proteins have been reported to directly phospho-
rylate several receptor tyrosine kinases. For example,
ERK1/2 MAPKs can phosphorylate the epidermal growth
factor (EGF) receptor (EGFR) at T669 [7, 8], the major site
of Ser/Thr phosphorylation of the receptor. Phosphoryla-
tion on this conserved residue, which is located in the
juxtamembrane region of the receptor, was shown to be
induced by tumour necrosis factor (TNF)-a, EGF, or
heregulin (HRG) in a breast cancer cell line [9]. T669
phosphorylation was dependent on ERK1/2 activity and
was subsequently shown to reduce the level of constitutive
EGFR tyrosine phosphorylation, suggesting that it could
downregulate EGFR signalling. The mechanism involved
appears to be a reduced ability of the phosphorylated jux-
tamembrane region to cross activate the other receptor
kinase of the dimer, even across heterodimeric receptors
[9]. ERBB3 (erb-b2 receptor tyrosine kinase 3) has been
shown to be phosphorylated in a position similar to T669 of
the EGFR, leading to reduced tyrosine phosphorylation of
the receptor [10], likely through a similar mechanism.
Interestingly, another report demonstrated that while EGF-
stimulated, ERK1/2-dependent phosphorylation of T669
reduced tyrosine phosphorylation and the activity of the
EGF receptor, T669 phosphorylation also inhibited recep-
tor downregulation, thereby acting as a positive regulator
of signalling [11]. It is, therefore, possible that the same
phosphorylation event controls both the duration of the
initial signal as well as the subsequent internalisation of the
receptor. An attractive hypothesis is that the negative
regulation of EGFR activity by T669 phosphorylation is
the event that causes the reduced internalisation, as
receptor internalisation is significantly increased by EGFR
activity [12]. However, exactly how these two outcomes
influence the final dynamics of the pathway awaits further
characterisation. Interestingly, ERK1/2 activity can also
activate the tyrosine phosphatase cdc25c via phosphoryla-
tion at T48 [13]. Cdc25c then dephosphorylates the EGFR
at Y1068, which is required for its activity, in a negative
feedback loop. Therefore, in addition to phosphorylating
the receptors directly, ERK1/2 can also activate tyrosine
phosphatases that inactivate the EGFR, adding to the
number of mechanisms by which upstream RTK signalling
can be suppressed by negative feedback.
The fibroblast growth factor (FGF) receptor has also
been shown to be subject to ERK1/2 feedback phospho-
rylation. FGF signalling leads to FGF receptor 1 (FGFR1)
phosphorylation on a conserved serine residue (S777) in its
C-terminal tail in an ERK1/2-dependent manner [14].
Furthermore, the authors demonstrated that recombinant
ERK1 and ERK2 phosphorylate FGFR1 on S777 in vitro.
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Importantly, the mutation of S777 to alanine resulted in
prolonged FGF1-induced tyrosine phosphorylation of
FGFR1. It also increased cell proliferation and migration of
U2OS cells expressing FGFR1, as well as neuronal out-
growth in cultured dorsal root ganglions, two established
models of FGFR-stimulated, ERK1/2-dependent cell
function. These experiments clearly demonstrate that
FGFR1 is subject to direct negative feedback phosphory-
lation by ERK1/2. It is unclear, however, how this results
in decreased FGFR1 tyrosine phosphorylation and attenu-
ated signalling. It is possible that the phosphorylated S777
site acts as a binding site for tyrosine phosphatases, or that
S777 phosphorylation induces local conformational chan-
ges in FGFR1 that make it a better substrate for
dephosphorylation, but these possibilities have yet to be
investigated.
Adaptor proteins, exchange factors, and GTP hydrolyase
activating proteins
Adaptor proteins connect activated RTKs to Ras and the
downstream MAPK cascade. Regardless of continuous
growth factor stimulation, Ras activation is usually tran-
sient. A negative feedback loop from ERK1/2 to adaptor
proteins and exchange factors contributes to this tran-
siency. For example, it was found that MAPK pathway
activation results in hyperphosphorylation of SOS1, which
was enhanced by ERK overexpression [15] and prevented
by MEK1/2 inhibition [16]. It was further shown that SOS1
is phosphorylated in vitro by activated ERK2 at multiple
sites [17]. SOS1 phosphorylation disrupts its association
Table 1 Negative feedback phosphorylation of ERK1/2 MAPK pathway components
Component Phosphorylation sites Mechanism References
EGFR T669 Reduces EGFR tyrosine phosphorylation through impaired cross activation of
the receptor dimer
[7–11]
FGFR1 S777 Reduces FGFR1 tyrosine phosphorylation (unknown mechanism) [14]
SOS1 S1132, S1167, S1178,
S1193
Disrupts association with Grb2 [15–19]
SOS1 S1134, S1161
(phosphorylated by
RSK2)
Creates a 14-3-3 binding site; reduces plasma membrane localisation [20, 21]
FRS2a T132, T135, T138, T376,
T452, T455, T458, T463
Reduces FRS2a tyrosine phosphorylation; inhibits Grb2 association [23, 24]
LAT T155 May disrupt association with PLCc1 [26]
Raf-1 S29, S289, S296, S301,
S642
Reduces association with Ras and plasma membrane localisation [15, 28–31, 33, 34]
B-Raf S151, T401, S750, T753 Disrupts dimerisation with Raf-1 (S151, T401, S750, T753); disrupts
association with Ras (S151)
[35, 36]
MEK1 T292, T386 May increase the dephosphorylation of the MEK1 activating sites; interferes
with the activating phosphorylation of MEK1 on S298 by PAK (T292)
[38–41]
KSR1 T260, T274, S320, S443,
S463
Disrupts association with B-Raf; regulates subcellular localisation
(compartmentalisation)
[54–57]
The ERK1/2 pathway proteins known to be phosphorylated in a negative feedback loop are listed, together with the phosphorylated residue(s).
All sites are directly phosphorylated by ERK1/2, unless specified otherwise. The potential mechanisms by which these modifications regulate the
target protein are also listed
Fig. 1 Negative feedback regulation of the ERK1/2 MAPK pathway.
The ERK1/2 MAPK pathway is subject to a large number of negative
feedback loops. These include direct phosphorylation by ERK1/2
(and RSK2) as well as transcriptionally induced feedback regulators,
such as DUSPs and Sprouty proteins. The major negative feedback
loops acting on the ERK1/2 pathway are shown
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with the adaptor proteins Grb2 and Shc and, consequently,
the receptors at the plasma membrane [16–18]. Interest-
ingly, simulation modelling suggests that the sites
phosphorylated by ERK1/2 may act decisively—as
opposed to cooperatively—in downregulating SOS1
activity [19]. SOS1 is also phosphorylated by the ERK1/2
effector ribosomal S6 kinase 2 (RSK2) [20]. RSK2-medi-
ated phosphorylation of two sites on SOS1 (S1134 and
S1161) leads to the recruitment of 14-3-3 and negative
regulation of ERK1/2 activity [21].
The FGF receptor substrate 2 proteins (FRS2a and
FRS2b) are adaptor proteins that are recruited to activated
RTKs via N-terminal PTB domains. They also contain
multiple tyrosine phosphorylation sites in their C-termini
that allow the binding of the adaptor protein Grb2 [22]. Lax
and colleagues [23] found that upon FGF stimulation
FRS2a became phosphorylated on eight threonine residues,
all of which were followed by a proline, representing a
minimum ERK1/2 consensus sequence. They further
showed that expression of dominant-negative Ras or
MEK1/2 inhibition abolished this phosphorylation, sug-
gesting that FRS2a is phosphorylated by an ERK1/2-
dependent feedback mechanism. Importantly, mutation of
the FRS2a threonine phosphorylation sites enhanced
FRS2a tyrosine phosphorylation and Grb2 association. The
same FRS2-dependent mechanism has been reported for
the regulation of EGFR signalling [24], suggesting that
threonine phosphorylation of FRS2a by ERK1/2 may
represent a conserved mechanism by which to inhibit
FRS2a tyrosine phosphorylation and downregulate RTK
signalling.
Another adaptor protein regulated by ERK1/2 feedback
phosphorylation is the linker for activation of T cells
(LAT), a single-pass transmembrane protein that is
expressed in various immune cells [25]. Upon engagement
of the T cell receptor (TCR), tyrosine phosphorylation of
LAT leads to the recruitment of several SH2 domain-
containing proteins, including Grb2, resulting in ERK1/2
activation. Matsuda and colleagues [26] found that LAT
can be phosphorylated on T155 by ERK1/2 in vitro. They
further showed that this site is phosphorylated upon T cell
activation in a MEK1/2-dependent manner, suggesting that
this event represents a feedback mechanism. To this end,
they showed that a LAT T155A mutant supported an
enhanced degree of TCR signalling (as measured by an
increase in intracellular Ca2? mobilisation) and that abol-
ishing ERK1/2 feedback through a MEK1/2 inhibitor
similarly enhanced TCR signalling. Through co-immuno-
precipitation experiments, the authors showed that the
mechanism behind the inhibitory role of LAT T155 phos-
phorylation may involve the disruption of the interaction of
LAT with its downstream signalling partner, phospholipase
C c1 (PLC c1), but not Grb2.
A recent paper by Hennig et al. [27] also implicated
Ras-GAP proteins as a target of negative feedback regu-
lation of Ras activity. They showed that inhibition or
knockdown of MEK1/2, ERK1/2, or RSK in HeLa cells
resulted in sustained activity of Ras (evidenced by GTP
loading). As the GDP/GTP exchange rate at the later time
points was not significantly changed, they concluded that
the sustained activity must be due to the inactivation of a
Ras-GAP, rather than an exchange factor such as SOS.
Through knockdown experiments, the authors then impli-
cated NF1 (neurofibromin) as the likely candidate, as
knockdown resulted in similarly sustained Ras activation
kinetics as the inhibition of ERK1/2 or Rsk. While it
remains to be shown whether NF1 activation by ERK1/2
and Rsk is by direct phosphorylation or if other proteins/
mechanisms are involved, this work adds another route by
which the upstream components of the ERK1/2 MAPK
cascade can be inhibited through negative feedback.
Raf proteins
The first suggestion that Raf is subject to feedback phos-
phorylation was provided by Ueki and colleagues [15],
who showed that Raf-1 is hyperphosphorylated after the
stimulation of insulin receptor-expressing CHO cells with
either insulin or TPA (12-O-tetradecanoylphorbol 13-ac-
etate). Raf-1 hyperphosphorylation was delayed compared
to the activation of Raf-1, MEK1/2 and ERK1/2, and it was
further enhanced by overexpression of ERK1, suggesting a
negative feedback loop. Further studies showed that Raf-1
hyperphosphorylation is dependent upon MEK1/2 activity
[28] and that pharmacological inhibition of ERK1/2 sig-
nalling results in increased and more sustained Raf-1
activity compared to its normal transient activation
[29, 30]. Hyperphosphorylated Raf-1 also displayed
reduced plasma membrane association, indicating a possi-
ble mechanism of Raf-1 feedback regulation [28].
A major advancement towards understanding the role of
Raf-1 in the negative feedback regulation of ERK1/2 sig-
nalling was made by the identification of six Raf-1 residues
that are phosphorylated following mitogenic stimulation
[31]. Five of these sites were directly phosphorylated by
ERK2 in vitro, and their phosphorylation was dependent on
signalling downstream of MEK1/2, suggesting that they are
involved in a feedback loop. The identified phosphoryla-
tion sites are located close to the N-terminus (S29/S43), the
C-terminus (S642), and in the flexible hinge region
between the regulatory and catalytic domain (S289/S296/
S301) of Raf-1. Phosphorylation at these sites yielded a
desensitised Raf-1 unable to localise to the plasma mem-
brane and to engage with activated Ras [31]. Feedback
phosphorylation also prevented sustained Raf-1 activity
[31, 32], as was shown by MEK1/2 inhibition as well as
D. Lake et al.
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mutation of the feedback sites. In addition, desensitised
(hyperphosphorylated) Raf-1 cannot be activated by stim-
ulation with another growth factor, even though the
upstream Ras protein is activated. Interestingly, hyper-
phosphorylated Raf-1 is not degraded, but is resensitised by
a complex process involving the prolyl isomerase Pin1 and
the protein phosphatase PP2A [31]. ERK1/2 activity-de-
pendent phosphorylation of a subset of these sites (S296/
S301) has also been observed by Hekman et al. [33], fol-
lowing expression of an activated Raf-1 mutant in
Drosophila Sf9 cells. Importantly, these authors showed
that the mutant proteins had significantly increased kinase
activity in quiescent and EGF-stimulated mammalian cells,
confirming a negative regulatory role for this phosphory-
lation event. However, while Balan et al. [34] also
described phosphorylation of a subset of these sites (S289/
S296/S301) in response to EGF stimulation of COS-7 cells,
they found that it rather acts in a stimulatory manner. The
reasons for this discrepancy are not clear, but could involve
the different cell lines (NIH3T3 vs. COS-7) or growth
factors [Platelet-derived growth factor (PDGF) vs. EGF]
used. In addition, the ERK1/2 feedback sites located at the
N- and C-terminus of Raf-1 (S29 and S642, respectively)
were not characterised by Balan et al. It is possible that
phosphorylation of the different sites is hierarchical, with
some sites being more important than others. It has also not
been clarified if phosphorylation at the multiple sites of
Raf-1 is cooperative or decisive, i.e., whether all sites need
to be phosphorylated for a measurable effect on Raf-1
activity. An interesting hypothesis is that Raf-1 feedback
phosphorylation could serve as a sensor for the strength of
signalling output, responding differently to weak or strong
Raf-1 activation. To gain more insight into these questions,
the relative contribution of each of the identified ERK1/2
feedback sites to the overall regulation of Raf-1 activity
clearly needs further investigation.
Feedback phosphorylation at ERK1/2 phosphorylation
motifs was also identified within the B-Raf C-terminus
(S750 and T753) upon engagement of the B cell antigen
receptor in chicken DT40B cells [35]. Mutation of these
sites to a phosphomimetic amino acid strongly reduced the
ability of B-Raf to induce neurite outgrowth in a PC12 cell
system. Interestingly, the S750 site is located in a similar
sequence and position to one of the Raf-1 feedback phos-
phorylation sites (S642) [31]. It has since been shown that
two additional sites within B-Raf (S151, T401) are phos-
phorylated by activated ERK1/2 in response to PDGF
treatment of NIH3T3 cells [36]. These sites are located in
the N-terminal region of B-Raf (in an equivalent position to
S29 of Raf-1) and the flexible hinge region (similar to
S289/S296/S301 of Raf-1), respectively. Together, these
sites represent an arrangement similar to the feedback sites
of Raf-1. They are also subject to Pin1/PP2A-dependent
dephosphorylation, which may recycle it to a signalling-
competent state. B-Raf had previously been found to het-
erodimerise with Raf-1 upon activation by Ras, leading to
Raf-1 transactivation [37]. Mutational analysis suggested
that ERK1/2 phosphorylation of all four sites within B-Raf
contributes to disruption of its dimerisation with Raf-1,
whereas phosphorylation at S151 is solely responsible for
inhibiting the interaction with activated Ras [36]. Inter-
estingly, the combined mutant had a stronger oncogenic
effect in focus formation assays than the single mutants
(other combinations have not been investigated), indicating
a degree of additivity.
MEK1/2
A number of inhibitory, proline-directed phosphorylation
sites have been reported for MEK1, including T286, T292,
and T386 [38–41]. The T292 site has been described in
each of these studies and appears to play the decisive role
in inhibiting MEK1 activity. T292 has been shown to be
phosphorylated by ERK1 and ERK2 in vitro and its
phosphorylation is dependent on ERK1/2 activity in intact
cells [38–40]. Phosphorylation of T292 inhibits the in vitro
kinase activity of MEK1 towards ERK1/2 [41], and the
T292A mutant is activated more strongly by serum treat-
ment [38], indicating a negative regulatory role for T292
phosphorylation. Dephosphorylation and inactivation of
MEK1 (and MEK2) has been proposed as a potential
mechanism mediating this feedback. Eblen and colleagues
[40] further found that ERK1/2 phosphorylation of MEK1
on T292 interferes with the binding of MEK1 to ERK2. It
also reduced the ability of PAK (p21-activated kinase) to
phosphorylate MEK1 on S298, which is required for the
activation of MEK1 by cell adhesion [39, 40, 42]. Inter-
estingly, the equivalent of the T292 site is absent in MEK2.
Nevertheless, it has been shown that MEK1 and MEK2
form heterodimers in vivo and that phosphorylation of
T292 in MEK1 also reduces the activity of MEK2 in the
context of the dimer [43], thus enabling the two MEK
proteins to be regulated simultaneously.
KSR1
A number of scaffold proteins have been shown to regulate
MAPK signalling in mammalian cells by organising the
signalling components into macromolecular complexes and
enhancing the efficiency and specificity of the MAPK
signalling cascade [44–46]. KSR (kinase suppressor of
Ras) proteins are perhaps the best studied scaffold proteins
for the ERK1/2 MAPK pathway. KSR1 was originally
identified as a positive regulator of Ras signalling in
Drosophila and C. elegans [47–49]. Subsequent analysis
found that KSR1 interacts with all three kinases of the
Negative feedback regulation of the ERK1/2 MAPK pathway
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ERK1/2 cascade [50, 51]. KSR1 has also been shown to
translocate from the cytosol to the plasma membrane upon
growth factor stimulation [52, 53], thus allowing the
assembly of the ERK1/2 pathway (Raf, MEK1/2, and
ERK1/2) close to the upstream activators (i.e., activated
Ras). Importantly, KSR1 translocation also localises active
ERK1/2 into close proximity to Raf-1 and other pathway
constituents, potentially facilitating feedback phosphory-
lation of upstream pathway components.
A number of KSR1 residues (T256, T260, T274, S320,
S443, S463) corresponding to the minimum ERK1/2
phosphorylation consensus motif (SP or TP) have been
shown to be phosphorylated in cycling cells [54] as well as
those stimulated with active Ras or growth factors [55–57].
These sites were also phosphorylated by recombinant
ERK1/2 in vitro and their phosphorylation in intact cells
depended on MEK1/2 activity [55–57]. KSR1 was also
phosphorylated at a subset of these sites when it was
immunoprecipitated from cycling HEK293T cells [54],
indicating that the responsible kinase(s) associated with
KSR1. As activated ERK1/2 associates with KSR1 in a
Ras-dependent manner [55], this further suggests that
ERK1/2 may directly phosphorylate KSR1.
Phosphorylation of KSR1 at the above sites has been
shown to have multiple effects on its function. Mutation of
these sites, inhibition of MEK1/2, and blocking ERK1/2
binding to KSR1 all resulted in increased and sustained
binding of KSR1 to B-Raf, suggesting that KSR1 feedback
phosphorylation interrupts the ternary complex of B-Raf,
KSR1, and MEK1/2 [57]. Subsequent co-immunoprecipi-
tation experiments demonstrated that ERK1/2 feedback
phosphorylation of KSR1 leads to the release of KSR1
from the plasma membrane, thereby impairing the ability
of KSR1 to potentiate signal transduction. KSR1 feedback
phosphorylation has also been shown to influence sig-
nalling dynamics, as KSR1 feedback mutants show
sustained ERK1/2 activation in response to EGF treatment
of HEK293 cells [56]. Interestingly, the S443 site has been
shown to be the most critical feedback site [56], as muta-
tion of this residue alone resulted in significantly prolonged
ERK1/2 activation in HEK293 cells, while further mutation
of other sites (T260, T274, and S320) had a small additive
effect.
The molecular mechanisms by which feedback phos-
phorylation of KSR1 regulate signalling were further
analysed in detail in neurons [56], where KSR1 is most
strongly expressed [58, 59]. ERK1/2 activity is well known
to be required for synaptic plasticity, particularly long-term
potentiation (LTP) of synaptic currents, by regulating the
amount of glutamate receptors at the cell surface of the
postsynaptic compartment, the dendritic spines. Notably,
KSR1 has been demonstrated to be located in dendritic
spines [56], suggesting for the first time that it may regulate
synaptic strength by promoting local ERK1/2 activity in
the postsynaptic compartment. Furthermore, it was
demonstrated that feedback phosphorylation of KSR1
results in the exclusion of the ERK1/2 scaffold complex
from dendritic spines, thus reducing ERK1/2 activity
specifically in the postsynaptic compartment. As postsy-
naptic ERK1/2 activity is essential to promote LTP, the
localised decrease of ERK1/2 activity had a significant
impact on synaptic plasticity, as shown by electrophysio-
logical experiments [56]. Overall, this study demonstrated
that in this system, negative feedback limits compartmen-
talised signalling output to ensure that it remains within
physiologically relevant boundaries.
Summary
Almost every step in the ERK1/2 MAPK pathway is tar-
geted by negative feedback phosphorylation (Fig. 1), from
the growth factor receptors at the plasma membrane to the
core components of the cascade (such as Raf-1/B-Raf and
MEK1/2) and scaffold proteins, such as KSR1. Of those,
the Raf proteins and KSR1 demonstrate complex regula-
tory mechanisms, are able to interact with several pathway
components, and reversibly localise to different subcellular
compartments. These two proteins may, therefore, serve as
key regulatory elements of the ERK1/2 cascade that can
finely tune the dynamics of ERK1/2 signalling in the cell as
a whole as well as in specific subcellular compartments.
Transcriptional induction of specific MAPK
pathway inhibitors
In addition to rapid feedback by direct phosphorylation
using pre-existing protein kinases, transcriptionally
induced mechanisms of feedback control have been
described for the ERK1/2 MAPK pathway. These pro-
cesses are likely to take effect with some delay compared
to direct phosphorylation. As such, they would be well
suited to modulating the later phases of ERK1/2 signalling
dynamics, rather than leading to the rapid termination of
signalling. They would also be able to contribute to
adjusting steady-state signalling levels under conditions of
sustained pathway input. The two major groups of proteins
that have been demonstrated to perform this function are
discussed below.
MAPK phosphatases
ERK1/2 require phosphorylation of both threonine and
tyrosine residues in the activation loop for full kinase
activity. Type 1/2 Ser/Thr phosphatases, protein tyrosine
phosphatases, and dual-specificity Thr/Tyr phosphatases
have all been shown to dephosphorylate and inactivate the
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ERK1/2 proteins [60]. The largest and best studied group
of phosphatases that specifically regulate MAPK activity
are the dual-specificity MAPK phosphatases (MKPs;
reviewed in [61]), a subgroup of the dual-specificity
phosphatases (DUSPs). There are ten MKPs in mammalian
cells, which can be divided into three groups. The first
group comprises the nuclear proteins DUSP1/MKP-1,
DUSP2, DUSP4/MKP-2, and DUSP5, which dephospho-
rylate ERK1/2, p38, and JNK (DUSP5 is ERK1/2-specific).
The second group includes the cytoplasmically located
ERK1/2-specific phosphatases DUSP6/MKP-3, DUSP7/
MKP-X, and DUSP9/MKP-4, while the final group con-
tains the p38/JNK-specific phosphatases DUSP8 (M3/6),
DUSP10/MKP-5, and DUSP16/MKP-7. In addition, a
number of atypical DUSPs have been identified. However,
atypical DUSPs do not possess a MAPK-binding motif, and
their role in the regulation of MAPKs is less clear.
Many members of the DUSP family are immediate early
or delayed early genes that can be transcriptionally induced
by ERK1/2 MAPK pathway activation [62]. While the
degree and the dynamics of induction of the individual
DUSPs vary depending on the cell type and the exact
stimulus, their inducibility enables these proteins to play an
important role in feedback regulation of ERK1/2 activity.
For example, in NIH3T3 cells, DUSP6 expression is
induced by FGF [63]. This induction is blocked by MEK1/2
inhibition, suggesting that DUSP6 may be involved in
pathway feedback. Further analysis demonstrated that
upregulation of DUSP6 is mediated by direct binding of the
ERK1/2-responsive transcription factor ETS1 to the DUSP6
gene promoter [63, 64]. Overexpression of wild-type
DUSP6 reduced the levels of EGF-stimulated phospho-
ERK1/2 after two hours of stimulation, but a phosphatase-
dead mutant DUSP6 had no effect [64]. These results
indicate that ERK1/2-induced DUSP6 expression leads to
feedback inhibition via dephosphorylation of ERK1/2. In
addition, due to their restricted distribution, DUSPs can
anchor inactive ERK1/2 in the nucleus or the cytoplasm
[65, 66], potentially delaying their re-activation. It should
be noted, however, that DUSPs only act on ERK1/2 and do
not regulate the upstream components of the pathway.
Sprouty proteins
Another group of relatively well-characterised transcrip-
tionally induced inhibitors of ERK1/2 signalling are the
sprouty (Spry) proteins [67], originally identified in Dro-
sophila as an inhibitor of Ras signalling downstream of
various RTKs [68–70]. In mammals, the expression of all
four Spry proteins (Spry1-4) can be induced by growth
factor signalling [71, 72]. In particular, Spry2 mRNA
expression is induced by various FGF members in human
ovarian granulosa lutein cells, murine osteoblastic cells,
bovine ovarian granulosa cells, and murine pancreatic buds
[73–76]. In several cases, the RTK-mediated induction of
Spry expression was abrogated by MEK1/2 inhibition,
suggesting that the expression of the Spry proteins depends
on ERK1/2 activity and that they may function as feedback
modulators [74–76]. Interactions between Spry proteins and
several ERK1/2 pathway components have been reported,
although how these interactions may allow Spry to modulate
signalling remains largely unclear [77]. Nevertheless, one
group showed that Spry1 and Spry2 become phosphorylated
on a conserved N-terminal tyrosine residue (Y53 or Y55,
respectively) upon EGF or FGF stimulation of C2C12 cells
[78]. Phosphorylation at this site creates a docking site for
the SH2 domain of Grb2, which leads to the disruption of the
association between Grb2 and the FGFR adaptor FRS2. This
result suggested that Spry may inhibit signalling upstream of
Ras, but other reports indicate that Spry may also inhibit the
pathway downstream of Ras, possibly by binding to Raf-1
[79, 80]. Other mechanisms have been reported, demon-
strating that the regulation of ERK1/2 signalling by the Spry
proteins is complex and likely depends on cell type and the
nature of the stimulus (see [81] for a detailed discussion).
Taken together, current data suggest that Spry proteins can
be induced by ERK1/2 pathway activation and that they
inhibit ERK1/2 signalling by acting at multiple nodes in the
pathway in a context-specific manner.
Summary
Amultitude ofmechanisms has developed to inhibit ERK1/2
MAPK signalling by negative feedback regulation (Fig. 1).
These include relatively fast-acting mechanisms that utilise
the downstream components of the cascade (mostly ERK1/2,
but also RSK2) to directly modify the activity of various
upstream components. In addition, mechanisms have
evolved that depend on the de novo expression of proteins,
which in turn target the ERK1/2 pathway at multiple levels.
These mechanisms are likely to be slower, affecting the later
phases of ERK1/2 signalling. This multitude of mechanisms
ensures that ERK1/2 signalling dynamics can be controlled
in a well-defined manner and that it can be adapted to the
particular circumstances of individual tissues and environ-
mental conditions.
Negative feedback modulates ERK1/2 MAPK
signalling dynamics
Temporal regulation of ERK1/2 signalling by negative
feedback
ERK1/2 MAPK pathway output is determined by the
integration of positive input (e.g., growth factors) and
positive and negative regulatory events, such as cross-talk
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and feedback mechanisms. These events determine ERK1/
2 signalling strength and duration and critically influence
the physiological outcomes. In a classic study, Traverse
and colleagues reported that in rat PC-12 cells, stimulation
with nerve growth factor (NGF) or EGF resulted in neu-
ronal differentiation or proliferation, respectively [82].
These strikingly different responses were linked to differ-
ences in the temporal dynamics of ERK1/2 activation,
whereby NGF caused sustained ERK1/2 activation and
nuclear translocation, while EGF induced a transient
response without nuclear translocation of activated ERK1/
2. Subsequent computer simulations suggested that nega-
tive feedback is the major determinant of ERK1/2
dynamics in this system [83]. This analysis was further
supported by Santos and colleagues [84] using modular
response analysis. Feeding data generated from pathway
perturbations by RNA interference into a sensitivity anal-
ysis produced evidence of a negative feedback loop from
ERK1/2 to Raf-1 when the pathway was stimulated with
EGF, but a positive loop when stimulated with NGF. These
findings were substantiated by the demonstration that
through rewiring the relevant feedback systems using
pharmacological compounds and inhibitors, the dynamics
of ERK1/2 activation and cell fate could be reversed in
each of the NGF- or EGF-stimulated states [84]. Interest-
ingly, differential expression of scaffold proteins, such as
KSR1, can also significantly modulate ERK1/2 dynamics
in PC-12 cells. Simply increasing the concentration of the
KSR1 scaffold has been shown to convert the temporary
ERK1/2 signal resulting from EGF stimulation into a sus-
tained one and to change cellular outcome from
proliferation to differentiation [58]. Interestingly, ERK1/2
signalling dynamics have a similar, albeit reverse effect on
adipogenesis [85]. Low concentrations of KSR1 promote
ERK1/2 activation, C/EBPb phosphorylation, and adipo-
genesis. In contrast, higher concentrations of KSR1 were
shown to prolong ERK1/2 signalling [86], promote PPARc
phosphorylation and inactivation, and inhibit differentia-
tion (adipogenesis) in favour of proliferation [85, 86].
Together, these reports clearly highlight the power of
feedback mechanisms to shape MAPK signalling outputs
and the resulting physiological outcomes and suggest the
existence of growth factor-specific network topologies.
Subsequent modelling approaches have further illumi-
nated the role of negative feedback in determining ERK1/2
signalling outputs. Elegant combinatorial work by Sturm
and colleagues [87] showed that the ERK1/2 MAPK
pathway exhibits properties of a negative feedback ampli-
fier (NFA). Importantly, the presence of negative feedback
confers graded response characteristics (as opposed to a
switch-like pattern when negative feedback is broken),
robustness to change and stabilisation of output. The
robustness conferred by negative feedback was further
demonstrated in experiments showing that the level of
steady-state doubly-phosphorylated ERK1/2 (‘output’) was
only weakly dependent on ERK1/2 protein concentration
[88], ensuring a reliable interpretation of extracellular
signals under fluctuating conditions. The authors further
showed that this robustness was lost in cells expressing
constitutively active B-Raf mutants or a constitutively
active Raf-1 protein, but not Ras mutants. As constitutively
active B-Raf (or Raf-1) is not sensitive to negative feed-
back regulation, these experiments suggest that the
robustness of the pathway output is critically dependent on
negative feedback targeting Raf-1 [31].
Spatial regulation of ERK1/2 signalling by negative
feedback
Many cellular processes occur in specialised subcellular
compartments, and the localisation of ERK1/2 activity to
those specific areas is critical to cellular function [1].
Modulating the subcellular localisation of activated ERK1/
2, even without changing overall cellular ERK1/2 activity,
can significantly change the availability of ERK1/2 for a
particular molecular function, with important consequences
for the outcome of signalling. Several cases have been
described where feedback phosphorylation leads to the
disassembly of the signalling complexes, resulting in the
removal of components from the plasma membrane and
termination of signalling [16–18, 31]. In addition, rever-
sible spatial segregation of ERK1/2 pathway components
by negative feedback has been demonstrated [56]. As
described earlier, the scaffold protein KSR1 is subject to
feedback phosphorylation by ERK1/2 at multiple sites.
KSR1 is highly expressed in neurons [58], where it is
involved in LTP (long-term potentiation), a process
important for learning and memory [59]. Its localisation in
primary hippocampal neurons was, therefore, further
investigated. It emerged that mutant KSR1 that is unable to
undergo feedback phosphorylation was preferentially pre-
sent in dendritic spines of the neurons, where it colocalised
with activated ERK1/2. In contrast, hyperphosphorylated
KSR1 was largely absent from dendritic spines and resided
in the dendritic processes. Importantly, MEK1/2 inhibition
or reduction of neuronal activity by tetrodotoxin (TTX)
resulted in the relocalisation of wild-type KSR1 to den-
dritic spines, demonstrating that the localisation of the
KSR1 scaffold is reversibly regulated by neuronal activity
and ERK1/2-dependent negative feedback. Localised
ERK1/2 signalling in dendritic spines has been shown to be
important for LTP and memory retention [89]. Conse-
quently, the expression of a mutant KSR1 lacking ERK1/2
feedback phosphorylation sites in cultured hippocampal
neurons led to increased KSR1 concentrations and phos-
pho-ERK1/2 staining in dendritic spines and prolonged
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LTP of synaptic currents compared to wild-type KSR1. A
model was proposed in which KSR1 tightly regulates
MAPK cascade output in the postsynaptic compartment
(dendritic spines) via compartmentalisation of the ERK1/2
signalling module. In resting neurons, KSR1 is localised to
the postsynaptic compartment, where it scaffolds Raf,
MEK1/2, and ERK1/2, making the synapse highly sensitive
to Ras-activating signals that promote LTP. However, as
more ERK1/2 is activated, feedback phosphorylation of
KSR1 gradually removes it from the dendritic spines,
making the system less sensitive and protecting against
excessive ERK1/2 activity in the postsynaptic compart-
ment. These results clearly demonstrate that negative
feedback is able to direct the signalling complexes to dif-
ferent subcellular compartments, in addition to regulating
their assembly and disassembly.
Negative feedback regulation of ERK1/2 signalling
in cancer progression and treatment
Aberrant ERK1/2 activation results in deregulated prolif-
eration and malignant transformation in model systems and
is commonly observed in human tumours. Inhibition of the
ERK1/2 pathway, therefore, represents an attractive target
for the treatment of malignant tumours with increased
ERK1/2 activity. However, therapeutic agents targeting the
ERK1/2 pathway would be expected to also inhibit the
substantial negative feedback loops (see Fig. 1), with
important consequences for therapeutic response and the
development of drug resistance.
Sensitivity to negative feedback determines the response
to therapeutic inhibitors
Activation of the ERK1/2 pathway is typically a result of
mutations in members of the RAS and RAF gene families
or the amplification and hyperactivation of RTKs [90–93].
Importantly, oncogenic B-Raf mutations are much more
common than those in A-Raf or Raf-1. While A-Raf and
Raf-1 require phosphorylation of two regions within their
kinase domain for full activation [3], B-Raf contains two
phosphomimetic aspartic acid residues and a constitutively
phosphorylated serine at the equivalent positions [94].
Therefore, B-Raf has higher basal activity and requires
only a single mutation within its kinase domain to switch to
constitutively high activity. Such substitutions are fre-
quently observed in ERK1/2-dependent tumours, most
commonly the V600E mutation. Interestingly, tumours
with B-RAF mutation are sensitive to inhibition of MEK1/
2, whereas tumours with hyperactivated growth factor
receptors are not [95]. Reasons for this discrepancy and
potential ways to overcome these challenges are discussed
below.
In cells with mutations in upstream components (e.g.,
RTKs or Ras) and expressing wild-type Raf proteins,
negative feedback mechanisms significantly reduce the
activity of several upstream pathway components, leading
to relatively low (but still elevated) levels of MEK1/2 and
ERK1/2 activity (Fig. 2a). Inhibition of MEK1/2 or Raf
will weaken the negative feedback loops, leading to an
increase in MEK1/2 and ERK1/2 activation. Therefore, a
significantly higher inhibitor concentration is necessary for
full inhibition of ERK1/2 signalling. This behaviour has
been predicted by Sturm et al. [87], as loss of negative
feedback is expected to increase the gain of the negative
feedback amplifier (NFA) module, conferring robustness
from external perturbations to the system. While this reg-
ulation helps to maintain signalling fidelity in normal cells,
it also contributes to the development of intrinsic resistance
to inhibitors. In addition, loss of negative feedback inhi-
bition in these tumours results in increased levels of Ras-
GTP, which has been shown to promote the dimerisation of
Raf proteins [37, 96, 97]. As binding of a Raf inhibitor to
one protomer can allosterically activate the other, Raf
inhibition results in the paradoxical promotion, rather than
inhibition, of ERK1/2 signalling [98, 99]. Importantly, the
observed transcriptional output of tumour cells with
mutated RTKs or Ras is only partially driven by ERK1/2
activity [100], with the activation of parallel pathways
significantly contributing to the expression of mitogenic
genes. In many cancers with upstream mutations, MEK1/2
or Raf inhibitors, therefore, do not result in therapeutic
changes of gene expression. In this context, Sturm and
colleagues [87] suggested that inhibiting targets outside of
the NFA is likely to be more effective. Their modelling
studies also raise the possibility of targeting modulators of
ERK1/2 activity, such as scaffold proteins, either alone or
in combination with Raf or MEK1/2 inhibitors. A related
conclusion from their modelling was that the inhibition of
the feedback loops themselves would likely lead to a new
steady-state activity of the pathway that is not subject to
negative feedback, thus enhancing the efficacy of inhibition
by MEK1/2 or Raf inhibitors. This was demonstrated in a
study in which SPRY2 silencing using siRNA improved
the inhibition of proliferation by a Raf inhibitor [101].
In contrast to tumours with upstream activation (RTKs
or Ras), those harbouring mutant B-Raf are generally
sensitive to MEK1/2 or Raf inhibition. One reason for this
sensitivity is that mutant B-Raf is constitutively active and
insensitive to negative feedback (Fig. 2b). Hyperactivation
of MEK1/2 (and ERK1/2) in B-Raf-mutated cells, there-
fore, continues unabated, resulting in increased
transcriptional output of transforming genes with ERK1/2
being the major driver [100]. However, the induced genes
include, in addition to those required for transformation,
negative feedback regulators, such as DUSPs and sprouty
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proteins. This has two important consequences. First,
negative feedback by the sprouty proteins means that Ras-
GTP levels are low. This was demonstrated in B-RafV600E
melanoma cells, where Ras-GTP levels could be increased
by disrupting feedback via either Raf or MEK1/2 inhibition
or knockdown of Spry1/2 [102]. In B-RafV600E cells, B-Raf
therefore exists mostly as a monomer, which is sensitive to
inhibition by Raf inhibitors [103]. In addition, the
increased expression of DUSPs in B-Raf mutant cells leads
to the dephosphorylation of ERK1/2 and a reduction of its
apparent activity to levels that support oncogenic trans-
formation (rather than senescence; [104, 105]).
Nevertheless, due to the increased transcriptional output of
these cells, several genes are induced that are essential for
tumour progression. As their expression critically depends
on ERK1/2 activity, those tumours are sensitive to inhibi-
tion of MEK1/2 or B-Raf. In other words, cells that evade
negative feedback become sensitive to inhibition at the
level of, or downstream of, the initiating mutation (i.e.,
B-RafV600E), as those cells have lost their robustness to
perturbations conferred by the negative feedback loops.
This has been shown to be the case in vitro [106, 107], and
a remarkably high degree of clinical efficacy has been
achieved using Raf and MEK1/2 inhibitors in patients with
B-Raf-mutant melanoma [108, 109]. It is, therefore,
important that tumours are evaluated for their specific
mutation to make an informed decision regarding the
treatment options. In addition, as MEK1/2 (rather than
ERK1/2) activity is a major hallmark and determinant of
inhibitor selectivity (see Fig. 2), this could be used as an
effective biomarker to stratify patients for treatment with
either Raf, MEK1/2, or other inhibitors. Unfortunately,
since Raf inhibition in normal cells expressing wild-type
Raf proteins activates the ERK1/2 pathway due to relief of
negative feedback and the increased formation and acti-
vation of Raf dimers, treatment with these compounds can
cause ectopic ERK1/2 signalling, with cutaneous lesions
(squamous cell carcinoma and/or keratoacanthoma) among
the most common problems [110, 111]. However, these
side effects are well manageable by surgical excision. In
addition, it would be feasible to utilise combination treat-
ments that counter the effects caused by disruption of
Fig. 2 ERK1/2 MAPK signalling in response to different oncogenic
stimuli. a In cells with mutation or amplification of upstream
components [e.g., RTKs (1)] and expressing wild-type Raf proteins,
negative feedback mechanisms are highly active (2,3) and signifi-
cantly reduce the activity of several upstream pathway components.
This leads to relatively low (but still elevated) steady-state levels of
MEK1/2 and ERK1/2 activity. When either Raf or MEK1/2 are
inhibited, this negative feedback is reduced. As a result, signal flux is
increased, restoring MEK1/2 and ERK1/2 activity and requiring
significantly higher inhibitor doses (intrinsic resistance). Loss of
negative feedback (2) due to pathway inhibition also results in
increased Ras-GTP levels, which promotes the dimerisation of wild-
type Raf proteins and results in the paradoxical promotion, rather than
inhibition, of ERK1/2 signalling. Finally, the observed transcriptional
output (4) of tumour cells with mutated RTKs or Ras is only partially
driven by ERK1/2 activity because of the relatively small increase in
the overall signalling flux due to extensive negative feedback.
Inhibition of Raf or MEK1/2, therefore, does not sufficiently reduce
the expression of those mitogenic genes to result in therapeutic
changes. b Mutant B-Raf (5) is constitutively active and, therefore,
not sensitive to direct feedback phosphorylation by ERK1/2 (6). In
addition, as mutated B-Raf is independent of upstream activation,
negative feedback to the upstream components has no effect on B-Raf
activity (7). Because mutated B-Raf bypasses negative feedback,
persistent hyperactivation of MEK1/2 (and ERK1/2) results in
significantly increased transcriptional output of mitogenic genes (8).
As mitogenic gene expression critically depends on high signalling
flux through the pathway, those tumours are sensitive to the inhibition
of MEK1/2 or B-Raf. In addition, the increased expression of DUSPs
(9) in B-Raf mutant cells leads to the dephosphorylation of ERK1/2
and a reduction of its apparent activity to levels that support
oncogenic transformation (rather than senescence). As a result,
MEK1/2 (rather than ERK1/2) activity is a major hallmark and
determinant of inhibitor selectivity (#)
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negative feedback in healthy cells to increase the efficacy
of the treatment as well as to reduce the potential side
effects.
Negative feedback and the development of resistance
to ERK1/2 pathway inhibitors
Inhibitors of B-Raf and MEK1/2 are showing substantial
promise in the clinic, particularly for those tumours har-
bouring B-Raf mutations (see above). However, even
patients who respond well to these inhibitors show signs of
relapse after several months, indicating that resistance to
these inhibitors has developed (adaptive resistance)
[112, 113]. The main reason for resistance in tumours that
are originally sensitive to B-Raf or MEK1/2 inhibitors is
the re-activation of signal flux through the ERK1/2 path-
way [102], resulting in increased transcription of mitogenic
genes. Due to the complexity of the regulation of ERK1/2
signalling, there are many potential means by which this
can be achieved. Here, we will focus on the mechanisms
that are related to relief from negative feedback.
In B-RafV600E tumours, Ras activity is suppressed by
negative feedback (Fig. 2b). Raf or MEK1/2 inhibition
results in the rapid and nearly complete downregulation of
ERK1/2 activity. As negative feedback partly depends on
inhibitory proteins induced by ERK1/2 signalling (such as
sprouty), this inhibition results in a gradual return to lower
levels of negative feedback, dependent on relatively slow
processes such as protein degradation. While Ras activity
remains low at first because of the relatively low activity of
upstream components such as RTKs, the cell is returned to
a signalling-competent state, where Ras and other upstream
factors are able to respond to signal activation (Fig. 3).
Indeed, activation of Ras via mutation or overexpression,
downregulation of the Ras negative regulator NF1, or
upstream RTK overexpression and activation have been
associated with resistance to Raf inhibitors in several
studies [114–120]. As a result of increased Ras activation,
signal flux is increased, promoting higher ERK1/2 activity
and requiring higher inhibitor doses. In addition, the relief
of ERK1/2-dependent feedback, together with the activa-
tion of upstream components, eventually leads to increased
levels of Ras-GTP-dependent Raf dimers, which are
insensitive to Raf inhibition [99]. Raf dimerisation can also
result from increased expression of B-Raf or Raf-1, leading
to the re-establishment of elevated ERK1/2 signalling
[114, 121, 122]. Evidence for the role of Raf dimerisation
in drug resistance was provided in co-immunoprecipitation
experiments, which showed that MEK1/2 inhibition
increased the formation of Raf-1/B-Raf dimers in mela-
noma cells [102]. Importantly, knockdown of Raf-1 by
siRNA had no effect on basal phospho-ERK1/2 levels in
B-RafV600E cells, but did reduce the extent of rebound of
phospho-ERK1/2 following prolonged vemurafenib treat-
ment. Interestingly, B-Raf mutant colon cancer cells
already express significant levels of the EGFR. Inhibitors
of Raf or MEK1/2, therefore, immediately upregulate
EGFR activity, due to relief from negative feedback [13].
While melanoma cells require another genetic event, such
as EGFR overexpression, to develop resistance,
B-RafV600E-positive colon cancer cells are already resistant
to Raf or MEK1/2 inhibition and do not respond to treat-
ment with vemurafenib [123].
As described above, Raf inhibition leads to an eventual
steady state that is defined by a low level of negative
feedback to upstream components, thus permitting Ras
activation and responsiveness to RTK stimulation. Never-
theless, it follows that high flux through the pathway, once
resistant to Raf inhibitors, is still sensitive to inhibition
either upstream or downstream of Raf. The rationale
behind this strategy is that the first drug will reduce the
negative feedback in the system, increasing the sensitivity
of the pathway to inhibition by the second drug. This
observation led to the idea that co-targeting several points
in the pathway may achieve the required near-total inhi-
bition of ERK1/2 activity (and signal flux) and improve
responses in patients with B-RafV600E melanoma [124].
Support for this idea has been gained from data showing
more complete ERK1/2 inhibition and greater tumour
Fig. 3 Loss of negative feedback contributes to resistance to Raf and
MEK1/2 inhibitors. Raf or MEK1/2 inhibition (1) results in lower
levels of negative feedback to upstream components (2). As a result,
the cell is returned to an RTK signalling-competent state, where Ras
and other upstream factors are able to respond to signal activation (3).
Therefore, signal flux is increased (4), promoting higher ERK1/2
activity and requiring higher inhibitor doses. The increased Ras
activity can also activate parallel pathways, such as the PI3K/Akt
pathway (5). In addition, loss of negative feedback leads to the de-
repression of other RTK receptors (6), allowing different growth
factors to activate downstream signalling pathways. Activation of the
PI3K/Akt pathway can promote cell survival (7) and reduce the
dependency of the tumour on ERK1/2 signalling, likely contributing
to the acquired resistance to Raf and MEK1/2 inhibitors
Negative feedback regulation of the ERK1/2 MAPK pathway
123
regression in mouse xenograft models using combined Raf
and MEK1/2 inhibition compared to Raf inhibition alone
[102]. Promising early clinical trials suggest that these
results may translate into increased therapeutic benefit
[125, 126]. In addition, recent studies [103, 127] reported
novel Raf inhibitors that are able to bind and inhibit both
Raf monomers and dimers. These drugs may be able to
address some of the resistance mechanisms, particularly in
tumours with acquired resistance that is due to Raf
dimerisation.
Unfortunately, the approach to specifically target ERK1/
2 MAPK signalling—even with combination therapy—is
not completely effective, since the relief of ERK1/2 feed-
back by Raf or MEK1/2 inhibition also reduces the
inhibition of parallel pathways that can promote survival
and reduce the dependency of the tumour on ERK1/2
signalling (Fig. 3). Several studies have shown that pro-
longed Raf inhibitor treatment of B-RafV600E melanoma
cell lines results in the activation of the phosphatidylinos-
itol-3-kinase (PI3K)/Akt pathway. This may occur as a
result of increased activity of different RTKs, due to the
release of negative feedback acting at this level. For
example, Villanueva and colleagues [128] showed that,
upon prolonged B-Raf inhibition, several melanoma cell
lines displayed increased phosphorylation and expression
of insulin-like growth factor 1 (IGF-1) receptor (IGF-1R)
as well as enhanced phosphorylation of Akt. In addition,
Turke et al. [10] demonstrated that MEK1/2 inhibition
reduces phosphorylation of the EGFR feedback site T669,
increases the activity of EGFR/ERBB3, and, consequently,
activates the PI3K/Akt pathway. Rapid Akt activation by
vemurafenib has also been shown in colon cancer cell
lines, due to constitutive EGFR expression and the relief of
negative feedback by the drug [13]. These observations
present the PI3K/Akt pathway as a potential co-tar-
get alongside the ERK1/2 pathway in the treatment of
B-Raf mutant melanoma and other B-Raf-driven tumours
[129, 130]. Consistent with this, co-inhibition of MEK1/2
and IGF-1R or PI3K was more effective in inducing cell
death in B-Raf inhibitor-resistant melanoma cells than
when either inhibitor was used alone [128]. In addition,
combination therapy with vemurafenib and the EGFR
inhibitor panitumumab has shown promising results in
early trials of B-RafV600E–positive colon cancer [131] and
cotreatment of colon cancer cells with vemurafenib and an
EGFR (cetuximab or gefitinib) or Akt (LY294002) inhi-
bitor was synergistic in reducing their growth [13, 132].
Another study found that tyrosine phosphorylation of the
EGFR family member ERBB3 was consistently upregu-
lated upon prolonged treatment of four melanoma cell lines
with the Raf inhibitor vemurafenib [133]. Under these
conditions, Akt phosphorylation was also induced, whereas
incubating the cells with a monoclonal anti-ERBB3
antibody completely abrogated the increase in phosphory-
lation of ERBB3 receptor and Akt. Moreover, co-
incubation with the anti-ERBB3 antibody was shown to
potentiate the growth inhibition effects of vemurafenib in
in vitro colony formation assays, inferring the possible
clinical use of combining the two approaches.
Overall, these studies demonstrate the importance of
understanding the mechanisms that are activated upon relief
of ERK1/2-dependent negative feedback, as those efficiently
promote drug resistance, particularly in B-RafV600E tumours.
They also highlight the fact that multiple RTKs and sig-
nalling pathways can become activated to rescue anti-
apoptotic signalling. One proposed approach to circumvent
this problem is the genomic and proteomic testing of tumour
samples early in and during the treatment phase [113], which
would permit the identification of patient-specific mutations
as well as RTK activity to inform treatment decisions. Such
diagnostic tests would indicate which other pathways may
need to be co-targeted, ideally before the eventual emer-
gence of resistance.
Final remarks
The regulation of the ERK1/2 MAPK pathway is complex
and includes numerous negative feedback loops. This
negative feedback has likely developed to confer robust-
ness and effective control over this evolutionally conserved
signalling pathway. While essential for the normal func-
tioning of the cell, its ability to ‘‘rewire’’ signalling
pathways represents a major problem for clinical inter-
vention. Substantial progress has been made during the last
few decades in understanding the complex regulation of
ERK1/2 MAPK signalling. While there are still a large
number of open questions, we are starting to see the ben-
efits of applying this knowledge to targeted cancer
treatment in the clinic.
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